EBV VCA IgA ELISA Kit (Epstein–Barr Virus Viral-Capsid Antigen)

Full Name: EBV VCA IgA ELISA Kit (Epstein–Barr Virus Viral-Capsid Antigen)
Reactivity: Human
Sample Type: Plasma, Serum
Sensitivity: 1.0 U/ml


Epstein–Barr virus viral-capsid antigen (EBV VCA) has an important role in providing the viral capsid of the Epstein–Barr virus (EBV). This antigen is targeted by anti-VCA antibodies and these antibodies are crucial in the diagnosis of infectious mononucleosis using many different serology testing methods. Elevated levels of anti-VCA IgG antibodies is a good indicator of prior infection whereas elevated levels of anti-VCA IgM can indicate acute infection.

The anti-VCA IgM appears early during an EBV infection and it tends to disappear between 4-6 weeks, whereas anti-VCA IgG is present during the acute phase of EBV infections (peaks between 2-4 weeks and persist throughout a person life). Clinical findings of infectious mononucleosis can be identified in conjunction with the appearance of IgM and IgG anti-VCA antibodies. Also, for primary infections, the sensitivity of IgM and IgG anti-VCA testing are regarded as being 100% reliable.


Human EBV VCA IgA ELISA kit is intended for detecting in-vitro amounts of human IgA antibodies to Epstein–Barr virus viral-capsid antigen (EBV VCA IgA) using serum and plasma. This assay has a minimum analytical sensitivity limit of 1.0 U/ml.


All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

  • EBV VCA coated microtiter strips.
  • Calibrator A (Negative Control).
  • Calibrator D (Positive Control).
  • Calibrator B (Cut-Off Standard).
  • Calibrator C (Weak Positive Control).
  • Sample Diluent.
  • Enzyme Conjugate.
  • TMB Substrate.
  • Washing Buffer (10x).
  • Stop Solution.


The minimum detection sensitivity level of human IgA antibodies against Epstein–Barr virus viral-capsid antigen (EBV VCA IgA) using current EBV VCA IgA ELISA kit was 1.0 U/ml. The dynamic range for this assay is 1.0 – 125.0 U/ml.


– Intra-Assay-Precision: 5.8 %
– Inter-Assay-Precision: 3.4 – 5.0 %
– Inter-Lot-Precision 3.9 – 8.7 %
– Analytical Sensitivity: 1.01 U/mL
– Recovery: 100 – 104 %
– Linearity: 84 – 116 %
– Cross-Reactivity: No cross-reactivity to Measles, Mumps and Varicella.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL.
– Clinical Specificity: 99 %
– Clinical Sensitivity: 100 %


  1. A meta-analysis on the EBV DNA and VCA IgA in diagnosis of Nasopharyngeal Carcinoma. Pak J Med Sci. (2013) 29 (3): 885-90. Review. Song C. and Yang S.
  2. Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF-C and -D. Med Sci Monit. (2015) 21: 2105-9. Sun R., et al.
  3. Expression of Serum Sialic Acid, Early Antigen-IgA, and Viral Capsid Antigen-IgA in Nasopharynx Cancer Patients: The Diagnostic Implication of Combined Assays. Med Sci Monit. (2015) 21: 4068-73. Sun Y., et al.
  4. Development of a time-resolved fluoroimmunoassay for Epstein-Barr virus viral capsid antigen IgA antibody in human serum. J Virol Methods. (2015) 222: 16-21. Liang Q.N., et al.


Online Enquiry Form

"*" indicates required fields

Please check mark information required:


Your secretory IgA ELISA gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA assay performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA assay's from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford